353 related articles for article (PubMed ID: 27645111)
1. Statin intolerance - a question of definition.
Algharably EA; Filler I; Rosenfeld S; Grabowski K; Kreutz R
Expert Opin Drug Saf; 2017 Jan; 16(1):55-63. PubMed ID: 27645111
[TBL] [Abstract][Full Text] [Related]
2. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.
Banach M; Rizzo M; Toth PP; Farnier M; Davidson MH; Al-Rasadi K; Aronow WS; Athyros V; Djuric DM; Ezhov MV; Greenfield RS; Hovingh GK; Kostner K; Serban C; Lighezan D; Fras Z; Moriarty PM; Muntner P; Goudev A; Ceska R; Nicholls SJ; Broncel M; Nikolic D; Pella D; Puri R; Rysz J; Wong ND; Bajnok L; Jones SR; Ray KK; Mikhailidis DP
Expert Opin Drug Saf; 2015 Jun; 14(6):935-55. PubMed ID: 25907232
[TBL] [Abstract][Full Text] [Related]
3. Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects.
Li JJ; Liu HH; Wu NQ; Yeo KK; Tan K; Ako J; Krittayaphong R; Tan RS; Aylward PE; Baek SH; Dalal J; Fong AYY; Li YH; O'Brien RC; Lim TSE; Koh SYN; Scherer DJ; Tada H; Kang V; Butters J; Nicholls SJ
Expert Opin Drug Metab Toxicol; 2020 Sep; 16(9):837-851. PubMed ID: 32729743
[TBL] [Abstract][Full Text] [Related]
4. Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle-related side-effects.
Sivashanmugarajah A; Fulcher J; Sullivan D; Elam M; Jenkins A; Keech A
Intern Med J; 2019 Sep; 49(9):1081-1091. PubMed ID: 31507054
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and Management of Statin Intolerance.
Alonso R; Cuevas A; Cafferata A
J Atheroscler Thromb; 2019 Mar; 26(3):207-215. PubMed ID: 30662020
[TBL] [Abstract][Full Text] [Related]
6. [ANMCO Position paper: Diagnostic and therapeutic pathways in patients with hypercholesterolemia and statin intolerance].
Gulizia MM; Colivicchi F; Arca M; Abrignani MG; Perna GP; Mureddu GF; Nardi F; Riccio C;
G Ital Cardiol (Rome); 2016 Jun; 17(6):447-55. PubMed ID: 27311087
[TBL] [Abstract][Full Text] [Related]
7. Optimizing Cholesterol Treatment in Patients With Muscle Complaints.
Rosenson RS; Baker S; Banach M; Borow KM; Braun LT; Bruckert E; Brunham LR; Catapano AL; Elam MB; Mancini GBJ; Moriarty PM; Morris PB; Muntner P; Ray KK; Stroes ES; Taylor BA; Taylor VH; Watts GF; Thompson PD
J Am Coll Cardiol; 2017 Sep; 70(10):1290-1301. PubMed ID: 28859793
[TBL] [Abstract][Full Text] [Related]
8. Expert opinion: the therapeutic challenges faced by statin intolerance.
Patel J; Martin SS; Banach M
Expert Opin Pharmacother; 2016 Aug; 17(11):1497-507. PubMed ID: 27254275
[TBL] [Abstract][Full Text] [Related]
9. Statin Intolerance: A Literature Review and Management Strategies.
Saxon DR; Eckel RH
Prog Cardiovasc Dis; 2016; 59(2):153-164. PubMed ID: 27497504
[TBL] [Abstract][Full Text] [Related]
10. Statin-induced myopathy: a review and update.
Abd TT; Jacobson TA
Expert Opin Drug Saf; 2011 May; 10(3):373-87. PubMed ID: 21342078
[TBL] [Abstract][Full Text] [Related]
11. Statin Intolerance.
Brown AS; Watson KE
Rev Cardiovasc Med; 2018; 19(S1):S9-S19. PubMed ID: 30207553
[TBL] [Abstract][Full Text] [Related]
12. Statin Toxicity.
Ward NC; Watts GF; Eckel RH
Circ Res; 2019 Jan; 124(2):328-350. PubMed ID: 30653440
[TBL] [Abstract][Full Text] [Related]
13. Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators.
Whayne TF
Angiology; 2011 Jul; 62(5):415-21. PubMed ID: 21421631
[TBL] [Abstract][Full Text] [Related]
14. Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management.
Iatan I; Mancini GBJ; Yeoh E; Hegele RA
Expert Rev Cardiovasc Ther; 2023 Jun; 21(6):423-435. PubMed ID: 37212306
[TBL] [Abstract][Full Text] [Related]
15. Muscle and statins: from toxicity to the nocebo effect.
Pedro-Botet J; Climent E; Benaiges D
Expert Opin Drug Saf; 2019 Jul; 18(7):573-579. PubMed ID: 31070941
[TBL] [Abstract][Full Text] [Related]
16. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
17. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
18. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
[TBL] [Abstract][Full Text] [Related]
19. [Statin intolerance and associated muscular dysfunctions].
Boulanger-Piette A; Bergeron J; Desgreniers J; Côté-Levesque M; Brassard D; Joanisse DR; Frenette J
Med Sci (Paris); 2015 Dec; 31(12):1109-14. PubMed ID: 26672664
[TBL] [Abstract][Full Text] [Related]
20. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance.
Thompson PD; Rubino J; Janik MJ; MacDougall DE; McBride SJ; Margulies JR; Newton RS
J Clin Lipidol; 2015; 9(3):295-304. PubMed ID: 26073387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]